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Radiotherapy or axillary lymph node dissection in breast cancer patients 
with positive sentinel lymph nodes?
Aleksandra Łacko1, 2, Wojciech M. Wysocki3
Over the years the surgical management of localized breast cancer has become less aggressive. Complete resection 
of the primary tumour with negative margins replaced mastectomy and is currently a standard of care in a vast ma-
jority of women with early breast cancer. Also, an introduction of sentinel lymph node biopsy allowed for giving up 
axillary lymph node dissection in the patients with pathologically negative sentinel nodes. This development has 
led to a decrease of morbidity such as lymphedema. However, the standard management of axilla in the patients 
with positive sentinel lymph nodes remains controversial. Recent studies demonstrated that in the patients with 1 or 
2 positive sentinel lymph nodes who undergo breast conserving surgery followed by conventionally fractionated 
whole-breast radiotherapy, a completion axillary lymph node dissection can be avoided. Furthermore, evidence from 
three two-phase non-inferiority studies comparing radiotherapy with complete lymph node dissection did not show 
any significant differences in either overall and disease-free survival, or local control and decrease of the percentage 
of patients with local adverse effects in radiotherapy arms. However, there are several methodological drawbacks 
and clinical limitations of these studies, which prevent from general omission of completion axillary lymph node 
dissection in breast cancer patients with positive sentinel lymph nodes. The debate held during V Annual Conference 
of Nowotwory Journal of Oncology and resulting article discusses the optimal management of axilla in this population. 
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Introduction 
Lower aggressiveness of surgical treatment of early 
breast cancer is connected with a smaller mutilation of a 
patient, yet the treatment efficiency is, at the same time, 
preserved. In the last three decades, the tendency for the 
minimalization of the scope of surgical treatment has con-
cerned also the interventions in the axillary fossa. The chan-
ge of the standard of care is so significant that in literature it 
is frequently referred to as “revolution”. Nevertheless, such 
term seems to be slightly premature, as still there is a num-
ber of doubts concerning the indications for “conserving” 
treatment of the axillary fossa. 
The first milestone in the minimalization of the axillary 
fossa treatment was the general application of sentinel 
lymph node biopsy (SNB) in the patients without clinically 
enlarged lymph nodes (cN0). In the case of a lack of metasta-
ses, such a procedure allows for a resignation from an axillary 
lymph node dissection (ALND), which saves the patients 
from complications connected with such an intervention, 
lymphedema in particular [1]. Another significant change in 
the surgical standard of care was the resignation from the 
surgical treatment of the axillary fossa in the patients with 
1 or 2 metastases in sentinel nodes, treated with conserving 
treatment. Two clinical trials, ACOSOG Z0011 and IBCSG 
23-01 showed that the abandonment of a surgical treat-
ment in this group of patients, in comparison with ALND
guaranteed a comparable local control and did not affect
the survival period [2, 3]. It must be stressed that both trials 
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concerned the patients with favourable prognostic features: 
in about 80% patients in the ACOSOG Z0011 trial and in 
95% patients in the IBCSG 23-01 trial, only one metastatic 
sentinel node was found, whilst only micro-metastases were 
present in 40% and 100%, in ACOSOG Z0011 and IBCSG 23-
01 respectively. Thus, there is no confidence that this is also 
the optimum procedure in a group with poorer prognoses. 
Moreover, since 100% in the ACOSOG Z0011 study and 90% 
women in the IBCSG 23-01 study, were treated with conse-
rving treatment with tangential field radiotherapy (RT), the 
conclusions from these studies are not definite and it cannot 
be ruled out that it was irradiation that compensated for an 
inadequate scope of the surgery. Therefore, indiscriminate 
resignation from ALND after a positive sentinel node biopsy 
in every patient does not seem rational or justified. 
It must be observed that SNB is performed also in the 
patients with locally advanced breast cancer without clini-
cally involved sentinel nodes on the axilla, after systemic 
pre-operative treatment, mastectomy patients in whose 
case no adjuvant RT is planned and also in a situation of 
a local recurrence after a previous conserving treatment. 
All the patients with such characteristics were not included 
in the above trials and that is why, in the case of a confirma-
tion of SLN metastases, there are no grounds to abandon 
ALND, or to replace a surgical intervention with RT [4]. The 
exception here concerns the patients after mastectomy with 
micro-metastases in sentinel lymph nodes. This recommen-
dation is based on the results of the two studies concerning 
women after mastectomy, which compared adjuvant ALND 
with the abandonment of further treatment [5, 6]. Neither 
of the studies showed any differences with regards to pro-
gression free survival. 
In the patients with an increased risk of recurrence (tu-
mour ≥ 3 cm, lymphatic involvement or micro-infiltration 
of the lymph node capsule) the optimal treatment is also 
controversial. In such a situation, the resignation from ALND 
seems to be possible, yet RT must be applied in the axillary 
fossa [7]. 
With regards to the indisputably lower risk of compli-
cations connected with radiotherapy, in comparison with 
long-term consequences of axillary lymphadenectomy, the 
next objective of the clinical studies was the comparison 
of both local treatment methods in the patients with early 
breast cancer. 
Randomized studies comparing radiotherapy 
versus ALND in women with positive sentinel 
lymph node
The concept of the resignation from the surgical treat-
ment of the axillary fossa and the replacement of the surgical 
intervention with irradiation was by no means new, as in 
the past it was evaluated in two separate clinical studies 
carried out in the 1970s and 1980s. In both cases no diffe-
rences with respect to the overall survival and progression 
free survival were shown in the patients, although in the 
study carried out by Louis-Sylvestre et al., the frequency 
of local recurrences was significantly larger in the patients 
undergoing radiotherapy (3% vs 1%; p = 0.04) [8]. A great 
advantage of both studies is a long follow-up period, whilst 
the disadvantage, rendering the interpretation of the results 
more difficult, lies in the significant differences in the cha-
racteristics of the patients (larger advancement stage) and 
in the administered treatment (both surgical and systemic 
ones — in comparison with the contemporary methods). 
The main objective of the NSABP B-04 study was the com-
parison of Halsted’s mastectomy with mastectomy alone or 
mastectomy completed with irradiation [9]. No patient in the 
study was treated systematically. In the light of the current 
standards, such procedure would be regarded as subopti-
mal. Therefore, the results of two “old” studies quoted in this 
paragraph should not provide the grounds for the clinical 
decisions taken in contemporary settings (certainly only in 
the treatment area discussed herein).
In two other “contemporary” studies — a multi-centre, 
international and randomised phase III study, AMAROS and 
a single-centre Hungarian, phase III study, OTOASOR — 
adjuvant RT was compared with ALND in the patients with 
metastases in the sentinel lymph nodes [10, 11]. Both clinical 
trials are the studies of the non-inferiority type. The results 
of the analyses carried out after 6 and 8-year follow-up 
period, in the AMAROS and OTOASOR study, respectively, 
point to comparable treatment results in both groups of 
patients with regards to survival indicators and local control. 
What draws attention, however, is a very small number of 
recurrences in the axillary fossa, irrespectively of the type of 
treatment (Table I). Some significant differences, however, 
concerned the long-term complications after the treatment. 
In the AMAROS study, in the patients undergoing radiothe-
rapy, a limb lymphoedema was observed twice less often 
(40% vs 21,7% after one year, 28% vs 13,6% after two years, 
in the arm with ALND and RT respectively). In the evaluation 
of the quality of life, the differences were observed solely in 
Table I. The Z0011 [3] and AMAROS studies [10] and OTOASOR [11] 
Z0011 AMAROS OTOASOR 
Median number of resected SN 2 2 (1–3) 2 (1–5) 
Macro-metastases 50% 60% 60% 
Additional lymph nodes after ALND 27.3% 32.8% 38.5% 
Recurrence in axillary fossa: ALND 0.5% 0.43% 1.7% 
Recurrence in axillary fossa: follow-up 1.5% 1.19% 2% 
Follow-up median 9.25 years 6.1 years 8 years
BCT 100% 82% 84% 
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the assessment of the symptoms concerning the upper limb. 
Both better mobility of the limb and less intensive oedemas 
of the hand and the limb point to the benefit of irradiation. 
In the OTOASOR study, the differences in the frequency of 
the upper limb symptoms (lymphoedema, paraesthesia, 
pain, mobility impairment) between both groups were even 
larger (15.3% vs 4.7%, in ALND and radiotherapy groups 
respectively). 
The patient populations were in both studies alike. The 
majority were the post-menopausal women with well-diffe-
rentiated ductal carcinomas and hormone receptors expres-
sion. Although the tumour size differed significantly in both 
protocols (the OTOASOR study concerned the patients with 
tumours ≤ 3 cm, and the AMAROS study < T2), in reality the 
majority of patients in both groups were the women with tu-
mours < 2 cm (62% and 82%, in the OTOASOR and AMAROS 
study respectively). Also the share of the patients treated 
with breast conserving treatment as compared with the 
mastectomy group was almost identical (20% and 16–18% 
in the OTOASOR and AMAROS study respectively). In both 
studies, systemic treatment was carried out according to 
the current standards. 
The criticism of both studies concerned a short follow-
-up period, a small number of events, a population with 
good prognoses and a lack of the analyses of the subgroups 
with respect to the biological characteristics of the tumour. 
With regards to a small number of events in the AMAROS 
study (assumed recurrence number: 2%, real number of 
recurrences: 0.43% in the group with ALND and 1.19% in the 
group with RT) the equivalence of both treatment methods 
could not be confirmed, which weakens the strength of the 
results. Moreover, in the OTOASOR study, the analysis of the 
efficacy was of the per protocol type, instead of the required 
non-inferiority intention-to-treat analysis (i.e. in the groups 
selected in accordance with the planned treatment). The re-
sults of the AMAROS study could have also been affected 
by the scope of the local treatment. In accordance with the 
protocol, ALND covered only the first and second level of 
the axillary fossa, whilst adjuvant RT — all the tree levels of 
the axillary fossa plus supraclavicular area. Therefore the 
scope of anatomic effect of both local treatment methods 
compared in the study was different: it was smaller in the 
case of a surgery and larger in the case of RT. 
Axillary radiotherapy in the patients with positive SN 
is still controversial. Due to the lack of high level evidence, 
little is known about which patients require RT. Two studies 
examined this issue. In MA.20 [12] and EORTC 22922-10925 
[13] comparing breast irradiation alone versus radiotherapy 
of the breast and node fields showed significant decrease 
in locoregional recurrence and distant spread, and 1% to 
2% overall survival benefit at 10 years. However, due to a 
relatively modest benefit of radiotherapy patients with low 
risk disease and limited nodal burden are likely to be over-
treated. In prospective study patients with positive sentinel 
lymph node meeting ACOSOG ZOO11 study characteristics 
were treated with SNB alone. After 5 years nodal recurrences 
were observed in only 1.4% of patients [14]. 
Axillary management after neoadjuvant therapy
The increasing use of neoadjuvant therapy, in both high-
-risk clinically node negative (cN0) disease and in clinically 
node positive (cN1) disease, potentially offers an oppor-
tunity to avoid ALND, because neoadjuvant therapy may 
result in downstaging of the axilla. However, the decision 
regarding the surgical management of the axilla must take 
into account several factors such as the performance cha-
racteristics of the SLN procedure after neoadjuvant thera-
py, the molecular subtype of the primary tumour and the 
planned breast procedure. For the patients with aggressive 
breast cancer subtypes such as triple negative or HER2+ 
disease, the use of neoadjuvant therapy is associated with 
high rates of nodal pCR. In patients with cN1 converted to 
cN0, SLN procedure is to be performed, and axillary node 
dissection may be omitted. An intriguing thing is that in 
cN0 patients meeting eligibility criteria for avoidance of 
ALND in the trials of upfront surgery, the use of neoadjuvant 
therapy may not significantly impact rates of ALND [15]. 
However, retrospective analysis performed in 1980 women 
showed that patients with most aggressive subtypes, triple 
negative, and HER-2 positive BC, treated with neoadjuvant 
therapy and mastectomy, the need for ALND was significan-
tly reduced [15]. For patients with advanced cN1, luminal, 
HER-2 negative disease, neoadjuvant therapy may result in 
downstaging of the axilla which offers more opportunity 
for individualized management [16]. Currently, endocrine 
neoadjuvant therapy is increasingly used in patients with 
low and intermediate grade, node positive, luminal tumours. 
The data regarding the optimal axilla management after 
neoadjuvant endocrine therapy are limited. Thus patient 
selection for SN after preoperative systemic treatment is 
critical. As patients treated with neoadjuvant therapy were 
not included in the studies confirming safety and efficacy 
of SNB alone, women with positive SN still require ALND. 
Conclusions 
In the debate during the last St. Gallen experts’ meeting 
in Vienna in 2017 concerning the optimal standard of care 
in the patients with metastases present in 1–2 lymph nodes 
after breast conserving treatment in whose case irradia-
tion is planned with the application of both standard and 
high tangential field radiotherapy, almost 80% respondents 
voted for the resignation from ALND. In the post-mastec-
tomy patients, ALND was regarded as indicated solely in 
a situation when no adjuvant radiotherapy was planned. 
The changes in the standard of the local treatment of axillary 
fossa are currently introduced and new data systematically 
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provide arguments for the resignation from an adjuvant sur-
gery of the axillary fossa. This is understandable in a situation 
when two treatment methods with comparable efficacy are 
available. By all means, the choice of a method with a lower 
risk of recurrence (out of the available treatment methods) 
is justified and indicated. Radiotherapy, and in some cases 
only observation, replaces lymphadenectomy on account to 
the significantly lower risk of long-term treatment compli-
cations and better quality of life confirmed in a long follow 
up period. This concerns the majority of patients meeting 
the inclusion criteria for the AMAROS and OTOASOR studies. 
Certainly a question remains whether in all the patients the 
minimalization of the surgical intervention in the axillary 
fossa is indicated. The results of these studies do not concern 
all the patients with an involvement of the sentinel nodes 
(among others — the patients with preoperative systemic 
treatment, the patients undergoing mastectomy, in whose 
case no RT is planned or the treated for local recurrences). 
In such cases, still ALND is recommended. It seems that in 
the decisions concerning the local treatment of the axillary 
fossa, it is significant to take into consideration such factors 
as the biology of the tumour, the type of systemic treatment 
and the scope of the planned radiotherapy.
Conflict of interest: none declared 
Wojciech M. Wysocki, MD, PhD
Maria Skłodowska-Curie Memorial Cancer Centre
and Institute of Oncology
Kraków Branch
Department of Surgical Oncology
ul. Garncarska 11, 31–115 Kraków, Poland
e-mail: z5wysock@cyf-kr.edu.pl
Received & Accepted: 20 Apr 2018 
Based on the presentation at the V Annual Conference 
of the Nowotwory Journal of Oncology, ‘Oncological Debates’, 
held in Warszawa, 7–8th April 2017
References
1. Krag DN, Anderson SJ, Julian TB et al. Sentinel-lymph-node resection 
compared with conventional axillary-lymph-node dissection in 
clinically node-negative patients with breast cancer: overall survival 
findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 
2010; 11: 927–933.
2. Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary 
dissection in women with invasive breast cancer and sentinel node 
metastasis: a randomized clinical trial. JAMA 2011; 305: 569–575.
3. Giuliano AE, McCall L, Beitsch P et al. Locoregional recurrence after 
sentinel lymph node dissection with or without axillary dissection in 
patients with sentinel lymph node metastases: the American College 
of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 
252: 426–433.
4. Lyman GH, Temin S, Edge SB et al. Sentinel lymph node biopsy for 
patients with early-stage breast cancer: American Society of Clinical 
Oncology clinical practice guideline update. J Clin Oncol 2014; 32: 
1365–1383.
5. Galimberti V, Cole BF, Zurrida S et al. Axillary dissection versus no 
axillary dissection in patients with sentinel-node micrometastases 
(IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 
2013; 14: 297–305.
6. Sola M, Alberro JA, Fralle M et. al. Comlete axillary lymph node dissec-
tion versus clinical follow-up in breast cancer patients with sentinel 
node micrometastasis: final results from the multicenter clinical trial 
AATRM 048/13/2000. Ann Surg Oncol 2013; 20: 120–127.
7. 7. Morrow M. Management of the node-positive axilla in breast cancer in 
2017: Selecting the right option. JAMA Oncol 2018; 4: 250–251.
8. Louis-Sylvestre C, Clough K, Asselain B et al. Axillary treatment in 
conservative management of operable breast cancer: dissection or 
radiotherapy? Results of a randomized study with 15 years of follow-up. 
J Clin Oncol 2004; 22: 97–101.
9. Fisher B, Jeong JH, Anderson S et al. Twenty-five-year follow-up of 
a randomized trial comparing radical mastectomy, total mastectomy, 
and total mastectomy followed by irradiation. N Engl J Med 2002; 437: 
567–575.
10. Donker M, van Tienhoven G, Straver ME et al. Radiotherapy or surgery 
of the axilla after a positive sentinel node in breast cancer (EORTC 
10981-22023 AMAROS): a randomised, multicentre, open-label, phase 
3 non-inferiority trial. Lancet Oncol 2014; 15: 1303–1310.
11. Sávolt Á, Péley G, Polgár C et al. Eight-year follow up result of the 
OTOASOR trial: The optimal treatment of the axilla — surgery or radio-
therapy after positive sentinel lymph node biopsy in early-stage breast 
cancer: A randomized, single centre, phase III non-inferiority trial. Eur J 
Surg Oncol 2017; 43: 672–679.
12. Poortmans PM, Collette S, Kirkove C et al; EORTC Radiation Oncology 
and Breast Cancer Groups. Internal mammary and medial supracla-
vicular irradiation in breast cancer. N Engl Med. 2015; 373: 317–327.
13. Whelan TJ, Olivotto IA, Parulekar WR et al; MA.20 Study Investigators. 
Regional nodal irradiation in early-stage breast cancer. N Engl J Med 
2015; 373: 307–316.
14. Morrow M, van Zee KJ, Patil S et al. Axillary dissection and nodal irra-
diation can be avoided for most node-positive Z0011-eligible breast 
cancers: a prospective validation study of 793 patients. Ann Surg 2017; 
266: 457–462.
15. Pilewskie M, Zabor EC, Mamtani A et al. The optimal treatment plan 
to avoid axillary lymph node dissection in early-stage breast cancer 
patients differs by surgical strategy and tumor subtype. Ann Surg Oncol 
2017; 24: 3527–3533.
16. Zhang J, Wang C. Axillary radiotherapy: an alternative treatment option 
for adjuvant axillary management of breast cancer. Sci Rep 2016; 6: 
26304. doi: 10.1038/srep26304.
